These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 29020426)

  • 1. Aflibercept in Serous Foveal Detachment in Dome-Shaped Macula: Short-Term Results in a Retrospective Study.
    Giacomelli G; Mencucci R; Sodi A; Biagini I; Abbruzzese G; Giuntoli M; Rizzo S; Virgili G
    Ophthalmic Surg Lasers Imaging Retina; 2017 Oct; 48(10):822-828. PubMed ID: 29020426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
    Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB
    Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
    Shah CP; Heier JS
    Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluctuations in Pigment Epithelial Detachment and Retinal Fluid Using a Bimonthly Treatment Regimen with Aflibercept for Neovascular Age-Related Macular Degeneration.
    Zinkernagel MS; Wolf S; Ebneter A
    Ophthalmologica; 2016; 235(1):42-8. PubMed ID: 26540259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aflibercept therapy for polypoidal choroidal vasculopathy: short-term results of a multicentre study.
    Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Sekiryu T; Okada AA; Iida T
    Br J Ophthalmol; 2015 Sep; 99(9):1284-8. PubMed ID: 25777816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DOME-SHAPED MACULA IN MYOPIC EYES: Twelve-Month Follow-up.
    Lorenzo D; Arias L; Choudhry N; Millan E; Flores I; Rubio MJ; Cobos E; García-Bru P; Filloy A; Caminal JM
    Retina; 2017 Apr; 37(4):680-686. PubMed ID: 28333783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Considering photodynamic therapy as a therapeutic modality in selected cases of dome-shaped macula complicated by foveal serous retinal detachment.
    Arapi I; Neri P; Mariotti C; Gesuita R; Pirani V; Freddo F; Lutaj P; Giovannini A
    Ophthalmic Surg Lasers Imaging Retina; 2015 Feb; 46(2):217-23. PubMed ID: 25707047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography.
    Abri Aghdam K; Seidensticker F; Pielen A; Framme C; Junker B
    Lasers Surg Med; 2016 Sep; 48(7):668-77. PubMed ID: 27111455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and efficacy of ziv-aflibercept in retinal diseases.
    Mansour AM; Ashraf M; Dedhia CJ; Charbaji A; Souka AAR; Chhablani J
    Br J Ophthalmol; 2017 Oct; 101(10):1374-1376. PubMed ID: 28270485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: the CONTAIN study.
    Pitcher JD; Witkin AJ; DeCroos FC; Ho AC
    Br J Ophthalmol; 2015 Jun; 99(6):848-52. PubMed ID: 25595177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration.
    Braimah IZ; Agarwal K; Mansour A; Chhablani J;
    Br J Ophthalmol; 2018 Jan; 102(1):91-96. PubMed ID: 28596286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal Aflibercept and Ranibizumab Injections for Polypoidal Choroidal Vasculopathy.
    Cho HJ; Kim KM; Kim HS; Han JI; Kim CG; Lee TG; Kim JW
    Am J Ophthalmol; 2016 May; 165():1-6. PubMed ID: 26921806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol.
    Jørstad ØK; Faber RT; Moe MC
    Acta Ophthalmol; 2017 Aug; 95(5):460-463. PubMed ID: 28556485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serous Retinal Detachment in Dome-shaped Macula with 7 Years Follow-up.
    Alakeely AG; Alrashaed S
    Middle East Afr J Ophthalmol; 2016; 23(4):323-325. PubMed ID: 27994399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases With Non-Response to Bevacizumab.
    Ashraf M; Souka AA; ElKayal H
    Ophthalmic Surg Lasers Imaging Retina; 2017 Mar; 48(3):230-236. PubMed ID: 28297035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal ziv-aflibercept for the treatment of choroidal neovascularisation associated with conditions other than age-related macular degeneration.
    Braimah IZ; Stewart M; Videkar C; Dedhia CJ; Chhablani J;
    Br J Ophthalmol; 2017 Sep; 101(9):1201-1205. PubMed ID: 28119292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathy.
    Hosokawa M; Shiraga F; Yamashita A; Shiragami C; Ono A; Shirakata Y; Kimura S; Shiode Y; Kawata T; Hosogi M; Fujiwara A; Morizane Y
    Br J Ophthalmol; 2015 Aug; 99(8):1087-91. PubMed ID: 25712826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy.
    Yamamoto A; Okada AA; Kano M; Koizumi H; Saito M; Maruko I; Sekiryu T; Iida T
    Ophthalmology; 2015 Sep; 122(9):1866-72. PubMed ID: 26088619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GOOD VISUAL OUTCOME AT 1 YEAR IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PIGMENT EPITHELIUM DETACHMENT: Factors Influencing the Treatment Response.
    de Massougnes S; Dirani A; Mantel I
    Retina; 2018 Apr; 38(4):717-724. PubMed ID: 28368974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD.
    Waizel M; Todorova MG; Masyk M; Wolf K; Rickmann A; Helaiwa K; Blanke BR; Szurman P
    BMC Ophthalmol; 2017 May; 17(1):79. PubMed ID: 28535756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.